The pandemic provided a reason to the stock market to be excited about the pharma sector that had been facing lacklustre prospects amid challenges in the US business, USFDA compliance issues, pricing pressure, big-bang acquisitions not working out on expected lines and modest growth in the domestic market.
Nifty ends flat as resistance holds; cautious optimism likely for coming week
Nifty traded range-bound, closing nearly flat despite an RBI rate cut, as resistance near 26,300 capped gains. Weak market breadth and muted broader indices signal
December 6, 2025